In agreement with this, in an HBV transgenic mouse model, antiplatelet therapy inhibits liver fibrosis and HCC development by reducing the number of intrahepatic HBV-specific CD8+ T and virus-non-specific inflammatory cells [103]. This evidence concerns the gene CD8A and hepatocellular carcinoma.